Harbin Pingchuan Pharmaceutical Holding Co., Ltd. ("PINGCHUAN") (PGCN) was established in March 2001 in Harbin city, P.R.China. It is a modernized pharmaceutical manufacturer with first-class medical R&D ability, pioneered medicine products, and well-established marketing network.
Harbin Pingchuan Traditional Chinese Medicine Research Institute was established in June 1998, with a registered capital of US$120,000. Currently it has 60 employees, 20 of them are professionals and experts on diabetes. Functioning as the R&D base of PINGCHUAN, the institute focuses on R & D of new medicines, particularly those on diabetes.
Since the establishment of 2001, PINGCHUAN has developed a series of diabetes medicine, including antibiotics, chemical medical capsules and traditional Chinese medicine. Kang Da Glycosuria Capsule is one of the successful products of PINGCHUAN for treating diabetes. It was first developed in 1998 and introduced to the market in 2001. PINGCHUAN also produces medical intermediates and pharmaceutical preparations, medical instruments, health care food and other related products.
PINGCHUAN has well-established marketing network and sale branches, including about 180,000 retail pharmacies/drugstores across China, agency network in major cities like Beijing, Shanghai, Guangzhou, and Xi'an, special sales counter at drug chain stores in key regions, residence community clinic sale and promotion, as well as internet marketing through the company's website. The marketing network of PINGCHUAN covers more than 50% districts of China and exports to US, Japan, Russia, and south-eastern Asia.